Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in developing a broad portfolio of RAS(ON) inhibitors across multiple disease settings.

Daraxonrasib, a pioneering RAS(ON) multi-selective inhibitor, has already shown an unprecedented clinical profile in various combinations. Consequently, the company is enrolling patients in the US for a Phase 3 trial of RASolve 301 in Non-Small Cell Lung Cancer (NSCLC).

On the other hand, Zoldonrasib, an innovative RAS(ON) G12D-selective covalent inhibitor, has shown a highly differentiated safety and tolerability profile.

“We expect a pivotal readout from RASolute 302 in the first half of 2026, which represents an important milestone for daraxonrasib, for patients with pancreatic cancer, and for our RAS(ON)-targeting strategy overall,” Goldsmith said.

Revolution Medicines exited 2025 in a strong financial position with $2 billion in cash, cash equivalents, and marketable securities. Research and development expenses surged to $294.9 million in the fourth quarter of 2025 from $188.1 million in the fourth quarter of 2024. The increase was driven by higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib. Full-year R&D expense totaled $987.3 million compared to $592.2 million in 2024

Net loss in the fourth quarter nearly doubled to $364.9 million, compared with $194.6 million in the same quarter of the prior year. The full-year 2025 net loss came in at $1.1 billion, compared to $600.1 million in 2024.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company focused on discovering and developing targeted therapies for RAS-addicted cancers, which represent roughly 30% of new cancer diagnoses.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.